2020 review – Pharma’s progress outside of COVID-19
pharmaphorum
DECEMBER 23, 2020
It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. It was the third approval from Alnylam’s pipeline of RNA interference therapeutics to make it to market.
Let's personalize your content